Compare Neurocrine Biosciences Inc (NBIX) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Visa Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Visa Inc trades at $369.84 (market cap $693.57B). The key difference: Visa Inc is far larger — about 44× Neurocrine Biosciences Inc's market cap, and Visa Inc pays a 0.73% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | V | |
|---|---|---|
Market Cap | $15.77B | $693.57B |
Sector | Health | Financials |
52-Week High | $185.50 | $384.14 |
52-Week Low | $123.10 | $295.52 |
Enterprise Value | $15.78B | $704.15B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Visa (V) trades at $368.64, down 1.71% on the day, amid a bullish technical setup with strong support at $366 and resistance at $372. The company reported robust fundamentals with Q2 2026 earnings beating estimates, revenue growth to $40B in 2025, and a net income margin of 50.78%. Recent news highlights Visa's push into AI-driven commerce and stablecoin partnerships, signaling innovation in payments.
Outlook remains positive with an analyst consensus price target of $430.93 (17% upside), supported by high profitability and strategic initiatives. Risks include fintech competition and regulatory pressures, but institutional ownership trends and a debt-to-asset ratio of 25.26% reflect financial stability. The stock presents a long-term growth opportunity with manageable headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
